S-1/A: Evoke Pharma Eyes $6.3 Million Boost with New Securities Offering

Evoke Pharma is launching an offering of common stock and pre-funded warrant units to raise approximately $6.3 million for working capital and general corporate purposes.

Summary

• Evoke Pharma is undertaking a public offering to sell up to 8,333,000 common stock units and pre-funded warrant units.
• Each common stock unit includes one share of common stock and warrants to purchase additional shares.
• The assumed purchase price is $0.90 per common stock unit, based on the last sale price on January 9, 2024.
• The company estimates net proceeds of approximately $6.3 million from the offering.
• These proceeds are intended for working capital, general corporate purposes, and potentially in-licensing or acquiring complementary businesses.
• The offering includes Series A, B, and C warrants with varying exercise prices and expiration dates.
• The Series A Warrants and the Series C Warrants will have an exercise price of $ per share.
• The Series B Warrants will have an exercise price per share equal to $ , which is equal to 100% of the price per Common Stock Unit sold in the offering.
• The Series A Warrants and Series B Warrants are exercisable immediately, subject to certain limitations described herein.
• The Series C Warrants may only be exercised to the extent and in proportion to a holder of the Series C Warrants exercising its corresponding Series B Warrants.
• The Series A Warrants will expire five years from the closing date of this offering.
• The Series B Warrants will expire nine months from the closing date of this offering.
• The Series C Warrants will also expire nine months from the closing date of this offering, provided that to the extent and in proportion to a holder of the Series C Warrants exercising its corresponding Series B Warrants included in the Common Stock Unit, such Series C Warrant will expire five years from the closing date of this offering.
• The company is also offering pre-funded warrants for purchasers who would exceed a 4.99% ownership threshold.
• The offering is managed by Craig-Hallum Capital Group LLC and Laidlaw & Company (UK) Ltd.

Sentiment

Score: 5

Explanation: The document is neutral. It describes a financial transaction. While the capital raise is positive, the potential dilution and risks associated with the company temper the sentiment.

Positives

• The offering provides Evoke Pharma with additional capital to fund operations and commercialization efforts.
• The structure with common stock and warrants may be attractive to certain investors.
• The potential for acquisitions could expand Evoke Pharma's product pipeline.

Negatives

• The offering will dilute existing shareholders' ownership.
• The company's stock price is currently low, at $0.90 per share.
• The exercise of warrants could further dilute shareholders.
• The company has broad discretion in the use of the net proceeds from this offering and may not use them effectively.

Risks

• The company's estimates of the amount of cash necessary to fund its activities may prove to be wrong and it could spend its available financial resources much faster than it currently expects.
• The terms of any financing may adversely affect the holdings or the rights of our stockholders.
• The issuance of additional shares or other securities by us, or the possibility of such issuance, may cause the market price of our shares to decline and dilute the holdings of our existing stockholders.
• If we raise additional funds by incurring debt, the terms of the debt may involve significant cash payment obligations, as well as covenants and specific financial ratios that may restrict our ability to operate our business.
• We cannot provide any assurance that our existing capital resources, even after taking into account the proceeds of this offering, will be sufficient to enable us to continue the commercialization of Gimoti or to otherwise continue as a going concern.
• If you purchase our securities sold in this offering, you will experience immediate and substantial dilution in the net tangible book value of your shares.
• We have broad discretion in the use of the net proceeds from this offering and may not use them effectively.
• The sale of our common stock in this offering, including any shares issuable upon exercise of any Pre-Funded Warrants or Common Warrants, and any future sales of our common stock, or the perception that such sales could occur, may depress our stock price and our ability to raise funds in new stock offerings.
• There is no public market for the Pre-Funded Warrants or Common Warrants being offered in this offering.
• We may not receive any additional funds upon the exercise of the Pre-Funded Warrants or Common Warrants.
• Significant holders or beneficial holders of our common stock may not be permitted to exercise Pre-Funded Warrants that they hold.
• The Common Warrants being offered may not have value.
• Holders of Pre-Funded Warrants and Common Warrants purchased in this offering will have no rights as common stockholders until such holders exercise their Pre-Funded Warrants or Common Warrants and acquire our common stock.
• If we fail to meet all applicable Nasdaq Capital Market requirements and Nasdaq determines to delist our common stock, the delisting could adversely affect the market liquidity of our common stock and the market price of our common stock could decrease.

Future Outlook

The company intends to use the net proceeds for working capital, general corporate purposes, and potentially in-licensing or acquiring complementary businesses.

Industry Context

The document mentions the potential impact of increased use of GLP-1 agonists on the gastroparesis market, suggesting a possible increase in the number of people suffering from gastroparesis.

Stakeholder Impact

• Existing shareholders will experience dilution.
• New investors will have an opportunity to invest in Evoke Pharma.
• The company's employees may benefit from the increased financial stability and growth potential.

Next Steps

• The company will proceed with the public offering, subject to market conditions and regulatory approvals.
• The company will use the net proceeds for the stated purposes.

Key Dates

Keywords

Evoke Pharma, common stock, pre-funded warrants, securities offering, warrants, Gimoti, capital raise, dilution, EVOK, financing